| First Author | Willekens C | Year | 2023 |
| Journal | Leukemia | Volume | 37 |
| Issue | 6 | Pages | 1287-1297 |
| PubMed ID | 37100881 | Mgi Jnum | J:353876 |
| Mgi Id | MGI:7488727 | Doi | 10.1038/s41375-023-01878-0 |
| Citation | Willekens C, et al. (2023) SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia 37(6):1287-1297 |
| abstractText | Heterozygous mutation targeting proline 95 in Serine/Arginine-rich Splicing Factor 2 (SRSF2) is associated with V617F mutation in Janus Activated Kinase 2 (JAK2) in some myeloproliferative neoplasms (MPNs), most commonly primary myelofibrosis. To explore the interaction of Srsf2(P95H) with Jak2(V617F), we generated Cre-inducible knock-in mice expressing these mutants under control of the stem cell leukemia (Scl) gene promoter. In transplantation experiments, Srsf2(P95H) unexpectedly delayed myelofibrosis induced by Jak2(V617F) and decreased TGFbeta1 serum level. Srsf2(P95H) reduced the competitiveness of transplanted Jak2(V617F) hematopoietic stem cells while preventing their exhaustion. RNA sequencing of sorted megakaryocytes identified an increased number of splicing events when the two mutations were combined. Focusing on JAK/STAT pathway, Jak2 exon 14 skipping was promoted by Srsf2(P95H), an event detected in patients with JAK2(V617F) and SRSF2(P95) co-mutation. The skipping event generates a truncated inactive JAK2 protein. Accordingly, Srsf2(P95H) delays myelofibrosis induced by the thrombopoietin receptor agonist Romiplostim in Jak2 wild-type animals. These results unveil JAK2 exon 14 skipping promotion as a strategy to reduce JAK/STAT signaling in pathological conditions. |
